pI: 6.6396 |
Length (AA): 905 |
MW (Da): 102079 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
113 | 339 | 4emv (A) | 18 | 206 | 43.00 | 0 | 1 | 0.534329 | -0.55 |
116 | 393 | 4k4o (A) | 18 | 224 | 51.00 | 0 | 1 | 0.444682 | -0.19 |
119 | 903 | 4i3h (A) | 24 | 1004 | 42.00 | 0 | 1 | 0.852903 | 1.03 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Ortholog group members (OG5_128755)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G10270 | DNA gyrase subunit B |
Arabidopsis thaliana | AT5G04130 | DNA gyrase subunit B |
Babesia bovis | BBOV_IV011850 | DNA gyrase subunit B, putative |
Chlamydia trachomatis | CT_190 | DNA gyrase subunit B |
Escherichia coli | b3699 | DNA gyrase, subunit B |
Leishmania braziliensis | LbrM.15.1230 | mitochondrial DNA topoisomerase II |
Leishmania donovani | LdBPK_151310.1 | mitochondrial DNA topoisomerase II |
Leishmania infantum | LinJ.15.1310 | mitochondrial DNA topoisomerase II |
Leishmania major | LmjF.15.1290 | mitochondrial DNA topoisomerase II |
Leishmania mexicana | LmxM.15.1290 | mitochondrial DNA topoisomerase II |
Mycobacterium leprae | ML0005 | Probable DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (Type II DNA topoisomerase) |
Mycobacterium tuberculosis | Rv0005 | DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (type II DNA topoisomerase) |
Mycobacterium ulcerans | MUL_0005 | DNA gyrase subunit B |
Neospora caninum | NCLIV_006680 | hypothetical protein |
Oryza sativa | 4326261 | Os01g0268300 |
Plasmodium berghei | PBANKA_1454000 | DNA gyrase subunit B, putative |
Plasmodium falciparum | PF3D7_1239500 | DNA gyrase subunit B |
Plasmodium knowlesi | PKNH_1459600 | DNA gyrase subunit B, putative |
Plasmodium vivax | PVX_100925 | DNA gyrase subunit B, putative |
Plasmodium yoelii | PY04024 | DNA topoisomerase II, putative |
Trypanosoma brucei gambiense | Tbg972.9.2960 | DNA topoisomerase II, putative |
Trypanosoma brucei | Tb927.9.5590 | DNA topoisomerase ii |
Trypanosoma congolense | TcIL3000_0_04850 | DNA topoisomerase II, putative |
Trypanosoma cruzi | TcCLB.506445.60 | mitochondrial DNA topoisomerase II, putative |
Trypanosoma cruzi | TcCLB.508277.370 | mitochondrial DNA topoisomerase II, putative |
Toxoplasma gondii | TGME49_297780 | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein |
Treponema pallidum | TP1006 | DNA gyrase, subunit B (gyrB) |
Theileria parva | TP01_1125 | DNA gyrase subunit B, putative |
Wolbachia endosymbiont of Brugia malayi | Wbm0764 | DNA gyrase, topoisomerase II, B subunit, GyrB |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
mtu5 | Mycobacterium tuberculosis | essential | nmpdr |
Tb09.160.4090 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb09.160.4090 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb09.160.4090 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb09.160.4090 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
b3699 | Escherichia coli | essential | goodall |
PBANKA_1454000 | Plasmodium berghei | Essential | plasmo |
TGME49_297780 | Toxoplasma gondii | Probably essential | sidik |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Staphylococcus aureus | Topoisomerase IV | 663 aa | 35.3% | 660 aa | Compounds | References |
Staphylococcus aureus | DNA gyrase | 644 aa | 37.1% | 638 aa | Compounds | References |